Related references
Note: Only part of the references are listed.Mutation-enhanced international prognostic systems for essential thrombocythaemia and polycythaemia vera
Ayalew Tefferi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
Clonal hematopoiesis in human aging and disease
Siddhartha Jaiswal et al.
SCIENCE (2019)
Clinicopathological and molecular features of SF3B1-mutated myeloproliferative neoplasms
Leonardo Boiocchi et al.
HUMAN PATHOLOGY (2019)
Imetelstat inhibits growth of megakaryocyte colony-forming units from patients with essential thrombocythemia
Gabriela M. Baerlocher et al.
BLOOD ADVANCES (2019)
Low-burden TP53 mutations in chronic phase of myeloproliferative neoplasms: association with age, hydroxyurea administration, disease type and JAK2 mutational status
B. Kubesova et al.
LEUKEMIA (2018)
Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms
Guillermo Montalban-Bravo et al.
Oncotarget (2018)
Classification and Personalized Prognosis in Myeloproliferative Neoplasms
J. Grinfeld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms
William Vainchenker et al.
BLOOD (2017)
Clonal hematopoiesis, with and without candidate driver mutations, is common in the elderly
Florian Zink et al.
BLOOD (2017)
Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms
Jelena D. Milosevic Feenstra et al.
BLOOD (2016)
Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients
Xenia Cabagnols et al.
BLOOD (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Targeted deep sequencing in polycythemia vera and essential thrombocythemia
Ayalew Tefferi et al.
BLOOD ADVANCES (2016)
Clinical and molecular response to interferon-α therapy in essential thrombocythemia patients with CALR mutations
Emmanuelle Verger et al.
BLOOD (2015)
Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib
Keyur P. Patel et al.
BLOOD (2015)
DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype
Jyoti Nangalia et al.
HAEMATOLOGICA (2015)
Distribution of mutations in DNMT3A gene and the suitability of mutations in R882 codon for MRD monitoring in patients with AML
Ivana Jeziskova et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2015)
A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis
Ayalew Tefferi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Effect of Mutation Order on Myeloproliferative Neoplasms
Christina A. Ortmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia
Gabriela M. Baerlocher et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors
S. Cerquozzi et al.
BLOOD CANCER JOURNAL (2015)
IDH1/2 but not DNMT3A mutations are suitable targets for minimal residual disease monitoring in acute myeloid leukemia patients: a study by the acute leukemia french association
Houria Debarri et al.
ONCOTARGET (2015)
DNMT3A mutations occur early or late in patients with myeloproliferative neoplasms and mutation order influences phenotype
Jyoti Nangalia et al.
HAEMATOLOGICA (2015)
Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms
Pontus Lundberg et al.
BLOOD (2014)
Age-Related Clonal Hematopoiesis Associated with Adverse Outcomes
Siddhartha Jaiswal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2
J. Nangalia et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Inherited predisposition to myeloproliferative neoplasms
Amy V. Jones et al.
THERAPEUTIC ADVANCES IN HEMATOLOGY (2013)
Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value
Marta Pratcorona et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Primer3-new capabilities and interfaces
Andreas Untergasser et al.
NUCLEIC ACIDS RESEARCH (2012)
p53 Lesions in Leukemic Transformation
Ashot Harutyunyan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Clonal analysis of erythroid progenitors suggests that pegylated interferon α-2a treatment targets JAK2V617F clones without affecting TET2 mutant cells
J-J Kiladjian et al.
LEUKEMIA (2010)
A method and server for predicting damaging missense mutations
Ivan A. Adzhubei et al.
NATURE METHODS (2010)
Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference
Giovanni Barosi et al.
BLOOD (2009)
Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia
Veronique Gelsi-Boyer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Different immunophenotypical apoptotic profiles characterise megakaryocytes of essential thrombocythaemia and primary myelofibrosis
A. M. Florena et al.
JOURNAL OF CLINICAL PATHOLOGY (2009)
Acquired mutations in TET2 are common in myelodysplastic syndromes
Saskia M. C. Langemeijer et al.
NATURE GENETICS (2009)
Share Paper
